International Journal of Hematology

DOI: 10.1007/s12185-017-2183-7 Pages: 623-630

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

1. Yokohama City University Medical Center, Department of Hematology

2. Yokohama City University School of Medicine, Department of Hematology and Clinical Immunology

3. Yokohama City University Hospital, Clinical Laboratory Department

4. Kanagawa Cancer Center, Department of Hematology

5. Shizuoka Red Cross Hospital, Department of Hematology

6. Yamato Municipal Hospital, Department of Hematology/Oncology

7. Fujisawa City Hospital, Department of Hematology

8. Saiseikai Nanbu Hospital, Department of Hematology

Correspondence to:
Etsuko Yamazaki
Tel: +81-45-787-2800



Body mass index (BMI), which represents the proportion of weight to height, is a controversial prognostic factor for acute myeloid leukemia (AML). We evaluated prognostic value of BMI in Japanese AML. The study included 369 adult patients with newly diagnosed AML who were administered either daunorubicin or idarubicin with cytarabine as induction chemotherapy. The patients were categorized into two groups according to their BMI: the NW group (BMI < 25.0 kg/m2; normal and underweight) and OW group (BMI ≥ 25.0 kg/m2; overweight and obese). We analyzed treatment efficacy and toxicity of induction chemotherapy, and survival outcomes in each group. Patients in the OW group showed a better complete remission rate than the NW group (86.1 versus 76.5%, P = 0.045), no early death (0.0 versus 4.1%, P = 0.042), and better overall survival (OS) at 3 years (62.2 versus 50.1%, P = 0.012). Multivariate analysis showed BMI is an independent prognostic factor for OS (hazard ratio 0.62, 95% confidence interval 0.42–0.92, P = 0.017). These results indicate the prognostic value of BMI in adult AML patients.

To access the full text, please Sign in

If you have institutional access, please click here

  • Google+
  • LinkedIn
Share the Knowledge